REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

System Biology: In search of good questions

Walter Kolch on the approach taken by Systems Biology Ireland

Systems Biology Ireland core scientific areas 2011December 2011. Prof. Walter Kolch, Director, Systems Biology Ireland & Conway Institute at University College Dublin describes SBI’s approach to systems biology in an exclusive interview with B2Bioworld. What is unique compared to Institutes at Seattle, Tokyo, Singapore, Luxembourg, or other where. What is the role of theory to guide experiments? Is there a non-trivial meaning of “perturbation” experiments? Which diseases are targeted, and which strategies are followed to answer those questions which AstraZeneca, Hewlett Packard, Pfizer, Servier, and other pharma and IT partners are eager to know beforehand.

Related Articles

Systems Biology Applied

The Need of Systems Theory Thinking in Using Technologies and Pitfalls of Some Concepts
Prof. Rudi Balling, Luxembourg Centre for Systems Biomedicine

Plant Genetic Engineering: ”It’s not as simple as Yes or No !”

Nobel Prize winner Prof. Christiane Nüsslein-Volhard

 

Teeth for the Convention on Biological Diversity

 

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Bayer Healthcare

 

Stem Cells - Failings and Deliveries

by Hugh Ilyine

 

Pfizer Regenerative Medicine: “It really started last year…”

Dr Ruth McKernan, Pfizer



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

5 pages, advert free

UK Chemical Industries’ Lessons From the Recession

Dr John Saul, past President of the British Chemical Industries Association on Issues For a Sustainable Future of the Sector

Dr John SaulApril 2011. The chemicals industry in the UK his coming out of some quite difficult times. How sustainable is recovery? In the exclusive interview with B2Bioworld Dr John Saul, past President of CIA provides an outlook on the future of the UK chemicals industry leveraging British Pound, US Dollar and Euro, while seeking opportunities within the UK, in the EU, and emerging countries. Demanding tasks lie ahead. While pharma is the draught horse of the UK chemicals industry, how competitive is the rest of it on a global scale? What is the strategy to reduce dependency on fossil energies and in which ways does it account for nuclear or renewable ones? How is REACH regulations viewed from within the country? Last not least, what are prospects that policy makers coherently attend to industry interests given a rather fragmented scene of lobbying organisations and preferences for the finance and banking sector?

Related Articles

Clariant & Süd-Chemie: “rather limited synergies”

Dr. Günter von Au, Designated Board Member Clariant AG and CEO Süd-Chemie AG

Fighting Crisis in the Chemicals Industry!

Giorgio Squinzi, CEO of Mapei SpA and past President of Italy’s Federchimica

Turkish Chemicals Industry: Opportunities and Threats

Timur Erk, President of TKSD on re-building Turkey’s chemicals industry

What Future for the Chemicals Industry?

Dr. Stefan Marcinowski, Member of the Board of Executive Directors of BASF SE



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

interview 8 pages

MediGene Set to Implement Strategic Turnaround

Dr Frank Mathias09-09-2009. For many months the TecDax-company is announcing re-focusing its business. Shareholders at the Annual Meeting learned how this will by implemented during the months to come bringing MediGene to sustainable profitability. Includes a comparison of financial performance with sector peers.

 

 

 

 

 

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Edited, non PR, 1 page

Top 10 Tags

All Tags (2074)